---
layout: default
title: Acetaminophen Chlorpheniramine
parent: Model Prediction Only (L5)
nav_order: 103
evidence_level: L5
indication_count: 0
---

# Acetaminophen Chlorpheniramine
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **0** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# ACETAMINOPHEN + CHLORPHENIRAMINE: Insufficient Data, Unable to Generate Complete Drug Repurposing Prediction Report

## One-Sentence Summary

ACETAMINOPHEN is an antipyretic and analgesic agent, and CHLORPHENIRAMINE is a first-generation antihistamine; this fixed-dose combination is commonly used for symptomatic relief in common cold and allergic symptoms.
However, the TxGNN workflow **produced no drug repurposing prediction results**, and no registration record was found in the Taiwan Drug License Database. Current data is insufficient to conduct a complete repurposing assessment.

---

## Quick Overview

| Item | Content |
|------|---------|
| Originally Approved Indications | No Taiwan approval data found |
| Predicted New Indications | None (no TxGNN prediction generated) |
| TxGNN Prediction Score | None |
| Evidence Level | Cannot be determined |
| Taiwan Market Status | ✗ Not marketed |
| Number of Licenses | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

The TxGNN model currently produced no prediction results for this fixed-dose combination (ACETAMINOPHEN + CHLORPHENIRAMINE), therefore mechanistic correlation analysis cannot be performed in this section.

From known background information: ACETAMINOPHEN exerts antipyretic and analgesic effects through inhibition of prostaglandin synthesis in the central nervous system; CHLORPHENIRAMINE is a competitive H₁ receptor antagonist that suppresses histamine-mediated allergic responses. Both are symptomatic treatment agents rather than disease-modifying drugs, and TxGNN's predictive capability for this class of fixed-dose combinations may be limited.

To advance the drug repurposing assessment, it is recommended to query the two active ingredients separately and rerun the prediction workflow after supplementing each component's DrugBank data.

---

## Taiwan Market Information

Query results show that this combination has **no registration record** in the Taiwan Drug License Database (number of licenses: 0).

Possible reasons include:
- When querying by combination string, unable to match individual component registration data
- This fixed-dose combination may be marketed as non-prescription (OTC) in Taiwan and is not registered under this exact combination name

It is recommended to query the Taiwan TFDA database separately using individual component names (ACETAMINOPHEN, CHLORPHENIRAMINE) in subsequent work.

---

## Safety Considerations

The current Evidence Pack has not retrieved safety data, including warnings, contraindications, and drug-drug interactions (DDI query result: not found).

Please consult the drug product information for complete safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model produced no prediction results for this fixed-dose combination, and both Taiwan drug licensing and safety data are lacking. Current data is insufficient to support a drug repurposing assessment.

**To continue advancement, the following data must be supplemented:**

- [ ] Rerun TxGNN predictions separately for individual components (ACETAMINOPHEN, CHLORPHENIRAMINE) to obtain respective drug repurposing candidate lists
- [ ] Supplement individual component data via DrugBank API including DrugBank ID and mechanism of action (MOA)
- [ ] Query the TFDA database using individual components to confirm current Taiwan license status
- [ ] Verify Evidence Pack input format: for combination drugs, it is recommended to separate into single components for individual processing rather than using combination strings as query keys
- [ ] Supplement safety data (DDI, warnings, contraindications) to rule out potential interaction risks

## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

